Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine
Autor: | S. Y. Ma, Paul M. Carvey, Toan Q. Vu, Jack W. Lipton, Heather C. Robie, Zaodung Ling, E. Y. Chen, Chong Wai Tong |
---|---|
Rok vydání: | 2000 |
Předmět: |
Male
medicine.medical_specialty Dopamine Cell Count Dopamine agonist Rats Sprague-Dawley chemistry.chemical_compound Pramipexole Parkinsonian Disorders Dopamine receptor D3 Dopaminergic Cell Internal medicine medicine Animals Benzothiazoles Oxidopamine Biological Psychiatry Neurons Hydroxydopamine Cell Death Tyrosine hydroxylase Rats Neostriatum Substantia Nigra Thiazoles Psychiatry and Mental health Neuroprotective Agents Endocrinology Neurology chemistry Dopamine Agonists Nerve Degeneration Neurology (clinical) medicine.drug |
Zdroj: | Journal of Neural Transmission. 107:159-176 |
ISSN: | 1435-1463 0300-9564 |
DOI: | 10.1007/s007020050014 |
Popis: | The D3 preferring dopamine agonist pramipexole has been shown to attenuate the cell loss induced by levodopa in vitro. Pramipexole was herein evaluated in the 6-hydroxydopamine lesion model to determine its in vivo effect. Rats were treated with pramipexole or saline before and after an intracerebroventricular 6-hydroxydopamine injection. In the preliminary study, 6-hydroxydopamine produced a 68% reduction in striatal dopamine and a 62% loss in tyrosine hydroxylase immunoreactive (THir) cell counts in the substantia nigra. Pramipexole treated animals exhibited a 29% and a 27% reduction in striatal dopamine and THir cell counts, respectively. THir cell counts and striatal dopamine were significantly correlated. In the stereological study, 6-hydroxydopamine reduced THir cell counts by 47% in saline treated animals and 26% in pramipexole treated animals. These data demonstrate that pramipexole attenuates the biochemical and THir cell changes normally produced by 6-hydroxydopamine consistent with its neuroprotective actions in vitro. |
Databáze: | OpenAIRE |
Externí odkaz: |